AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7340377 — intervention group
Group type: COMPARATOR
Intervention: 6‐8 ml of 0.5% bupivacaine with epinephrine (n = 17)
Number of subjects: 42
Study 7340377 — intervention group
Group type: COMPARATOR
Intervention: 4‐6 ml of 0.5% bupivacaine with epinephrine
Number of subjects: 42
Study 7340377 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of morphine in 10 ml of saline
Number of subjects: 42
Study 30142092 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive reducing assistance force group (n = 15)
Number of subjects: 29
Study 30142092 — intervention group
Group type: COMPARATOR
Intervention: Full assistance force group (n = 14)
Number of subjects: 29
Study 28779933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐i)
Number of subjects: 60
Study 28779933 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture (AA)
Number of subjects: 60
Study 25997550 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic sildenafil 50 mg film-coated tablets
Number of subjects: 0
Study 25997550 — intervention group
Group type: COMPARATOR
Intervention: Viagra® 50 mg film-coated tablets (reference)
Number of subjects: 0
Study 23252455 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Number of subjects: 120
Study 23252455 — intervention group
Group type: COMPARATOR
Intervention: No periodontal treatment (Control)
Number of subjects: 120
Study 21371754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother Infant Transaction Program
Number of subjects: 93
Study 19138577 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (amoxicillin, metronidazole, and omeprazole)
Number of subjects: 83
Study 19138577 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone (Control)
Number of subjects: 83
Study 17380806 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Illuminé 15% for 8 hours per day, over 7 days
Number of subjects: 24
Study 17380806 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Illuminé 15% for 8 hours per day, over 14 days
Number of subjects: 24
Study 17380806 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Illuminé 15% for 8 hours per day, over 28 days
Number of subjects: 24
Study 17380806 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Illuminé 15% for 8 hours per day, over 42 days
Number of subjects: 24
Study 17380806 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitestrips for 30 minutes each time, for 14 times
Number of subjects: 24
Study 17380806 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitestrips for 30 minutes each time, for 28 times
Number of subjects: 24
Study 17380806 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitestrips for 30 minutes each time, for 42 times
Number of subjects: 24
Study 17380806 — intervention group
Group type: COMPARATOR
Intervention: Unbleached specimens
Number of subjects: 24
Study 15479657 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding peer counseling (PC)
Number of subjects: 0
Study 11133629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 0.25%
Number of subjects: 60
Study 11133629 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5%
Number of subjects: 60
Study 11133629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol-Lidocaine 0.5%
Number of subjects: 60
Study 11133629 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (saline)
Number of subjects: 60
Study 9036907 — intervention group
Group type: EXPERIMENTAL
Intervention: New EMG biofeedback traction modality
Number of subjects: 24
Study 9036907 — intervention group
Group type: COMPARATOR
Intervention: Conventional cervical traction
Number of subjects: 24
Study 9036907 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (conventional cervical traction)
Number of subjects: 24
Study 7842998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% Clonidine HCl
Number of subjects: 269
Study 7842998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Clonidine)
Number of subjects: 269
Study 3276187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 113
Study 29366911 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone symptom management (TSM) intervention
Number of subjects: 51
Study 28821530 — intervention group
Group type: EXPERIMENTAL
Intervention: WHISPER (sexual and reproductive health SMS intervention)
Number of subjects: 860
Study 28821530 — intervention group
Group type: EXPERIMENTAL
Intervention: SHOUT (nutrition SMS intervention)
Number of subjects: 860
Study 28821530 — intervention group
Group type: COMPARATOR
Intervention: Control group (equal-attention control for both WHISPER and SHOUT)
Number of subjects: 860
Study 26298718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 255
Study 26298718 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy
Number of subjects: 255
Study 24565457 — intervention group
Group type: EXPERIMENTAL
Intervention: AAAAI‐AWC intervention group
Number of subjects: 55
Study 24565457 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 22004229 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU 1,25 dihydroxy vitamin D3 + calcium combination
Number of subjects: 121
Study 22004229 — intervention group
Group type: COMPARATOR
Intervention: Triple DMARD therapy + calcium alone
Number of subjects: 121
Study 19057103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group (balance exercise considering cognitive function; task difficulty, internal observation)
Number of subjects: 23
Study 19057103 — intervention group
Group type: COMPARATOR
Intervention: Control group (balance exercise)
Number of subjects: 23
Study 16980380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (up to 15 mg per day)
Number of subjects: 5269
Study 16980380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5269
Study 12622322 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 828
Study 12622322 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Number of subjects: 828
Study 12622322 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 828
Study 10397291 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sialic acid in alcoholics
Number of subjects: 125
Study 10397291 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva sialic acid in alcoholics
Number of subjects: 125
Study 10397291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialic acid concentrations after 5 weeks of treatment
Number of subjects: 125
Study 10397291 — intervention group
Group type: COMPARATOR
Intervention: Traditional markers of alcohol abuse
Number of subjects: 125
Study 8862204 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (i.v. formulation given monthly)
Number of subjects: 0
Study 8862204 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate disodium, pamidronate disodium, clodronate disodium, alendronate sodium
Number of subjects: 0
Study 8862204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral formulations of bisphosphonates
Number of subjects: 0
Study 8862204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates in general
Number of subjects: 0
Study 2057277 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment (surfactant TA containing surfactant proteins B and C, no SP-A)
Number of subjects: 0
Study 2057277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 0
Study 2057277 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment (surfactant TA)
Number of subjects: 0
Study 6337763 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (140 gm) in divided doses over 12 hr
Number of subjects: 6
Study 6337763 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 6
Study 30260821 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with anorganic bovine bone and resorbable collagen barrier (Group A)
Number of subjects: 102
Study 30260821 — intervention group
Group type: COMPARATOR
Intervention: Immediate implant placement without bone graft (Group B)
Number of subjects: 102
Study 27716132 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive vouchers (€50 at end of training, €50 after 3 months, €50 after 6 months, €200 after 1 year)
Number of subjects: 0
Study 27716132 — intervention group
Group type: COMPARATOR
Intervention: No additional incentive (control group)
Number of subjects: 0
Study 24737541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based N-RCT
Number of subjects: 77
Study 24737541 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin-based N-RCT
Number of subjects: 77
Study 23355182 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention (5 weekly classes over 5 or 6 weeks of radiotherapy)
Number of subjects: 96
Study 23355182 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 96
Study 20100393 — intervention group
Group type: EXPERIMENTAL
Intervention: Collectivism
Number of subjects: 0
Study 20100393 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualism
Number of subjects: 0
Study 20100393 — intervention group
Group type: EXPERIMENTAL
Intervention: Collectivism and Individualism (chronic and primed)
Number of subjects: 0
Study 18808446 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral delayed-release mesalazine (2.4 g/day and 4.8 g/day)
Number of subjects: 687
Study 15546963 — intervention group
Group type: COMPARATOR
Intervention: Standing Extended View (SEV)
Number of subjects: 47
Study 15546963 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiflexed, postero-anterior view (MTP)
Number of subjects: 47
Study 15546963 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SEV and MTP views for osteophyte grading
Number of subjects: 47
Study 12545143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (300 mg/d for 3 days)
Number of subjects: 12
Study 12545143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12545143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 12
Study 11014886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral appliance therapy (ISMAR)
Number of subjects: 20
Study 8638029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 8638029 — intervention group
Group type: COMPARATOR
Intervention: Other antiarrhythmic drugs
Number of subjects: 0
Study 1592952 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs (specific drugs not mentioned)
Number of subjects: 0
Study 1592952 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized measure of benefit/harm
Number of subjects: 0
Study 1592952 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized, N‐of‐1 trial
Number of subjects: 0
Study 2581099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 83
Study 2581099 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (ALB)
Number of subjects: 83
Study 2581099 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 83
Study 30442510 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom education (25-45 minutes practice-while-watching session)
Number of subjects: 0
Study 30442510 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiosk education (4-minute on-screen feedback and practice session)
Number of subjects: 0
Study 30442510 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-only education (1-minute video viewing)
Number of subjects: 0
Study 30442510 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as video-only)
Number of subjects: 0
Study 30185972 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific DNA aptamers against dabigatran etexilate
Number of subjects: 0
Study 27104984 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) lozenges, 2 per day for 3 weeks
Number of subjects: 47
Study 27104984 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges, 2 per day for 3 weeks
Number of subjects: 47
Study 25180378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules (taken twice daily for 12 months)
Number of subjects: 928
Study 25180378 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (taken twice daily for 12 months)
Number of subjects: 928
Study 23625628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 46
Study 23625628 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 46
Study 20379187 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0
Study 20379187 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study 19100010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardial effusion (PE)
Number of subjects: 124
Study 19100010 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular diastolic dysfunction (LVDD)
Number of subjects: 124
Study 19100010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery hypertension (PAH)
Number of subjects: 124
Study 19100010 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrium enlargement
Number of subjects: 124
Study 19100010 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral insufficiency
Number of subjects: 124
Study 19100010 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic dilation
Number of subjects: 124
Study 19100010 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid insufficiency
Number of subjects: 124
Study 19100010 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular enlargement
Number of subjects: 124
Study 19100010 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular systolic dysfunction
Number of subjects: 124
Study 19100010 — intervention group
Group type: COMPARATOR
Intervention: C reactive protein level (CRP)
Number of subjects: 124
Study 19100010 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 124
Study 19100010 — intervention group
Group type: COMPARATOR
Intervention: Gammaglobulin level
Number of subjects: 124
Study 16371736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline plus dextran (HSD)
Number of subjects: 27
Study 16371736 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 27
Study 14693066 — intervention group
Group type: EXPERIMENTAL
Intervention: L-OHP + LV + 5-FU + VP-16 (treatment group)
Number of subjects: 48
Study 14693066 — intervention group
Group type: COMPARATOR
Intervention: DDP + LV + 5-FU + VP-16 (control group)
Number of subjects: 48
Study 11200144 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional fluorouracil (5-FU) in combination with cisplatin (Platinol) or newer agents docetaxel (Taxotere) and irinotecan (Camptosar)
Number of subjects: 0
Study 11200144 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 0
Study 11200144 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy
Number of subjects: 0
Study 11200144 — intervention group
Group type: COMPARATOR
Intervention: Preoperative treatment
Number of subjects: 0
Study 8774625 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (750 mg/day) for at least 30 days prior to PTCA (group P‐1)
Number of subjects: 141
Study 8774625 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (750 mg/day) for less than 14 days prior to PTCA (group P‐2)
Number of subjects: 141
Study 8774625 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10 mg/day) for at least 30 days prior to PTCA (group V‐1)
Number of subjects: 141
Study 8774625 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10 mg/day) for less than 14 days prior to PTCA (group V‐2)
Number of subjects: 141
Study 1616359 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg twice daily for weeks 0-8, then 400 mg three times a day for weeks 9-24)
Number of subjects: 50
Study 1616359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2865187 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose oral contraceptive
Number of subjects: 0
Study 2865187 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive
Number of subjects: 0
Study 30029967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 277
Study 30029967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 277
Study 30029967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 29504705 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclical (Arm A, n = 260)
Number of subjects: 525
Study 29504705 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol® (Arm B, n = 265)
Number of subjects: 525
Study 29504705 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (n = 525)
Number of subjects: 525
Study 27779454 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine hydrochloride 10 mg/d
Number of subjects: 186
Study 27779454 — intervention group
Group type: COMPARATOR
Intervention: Felodipine sustained-release tablets 5 mg/d
Number of subjects: 186
Study 27779454 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Lercanidipine and Felodipine
Number of subjects: 186
Study 25307297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent stroke
Number of subjects: 5104
Study 25307297 — intervention group
Group type: COMPARATOR
Intervention: No recurrent stroke
Number of subjects: 5104
Study 25307297 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor HRQOL
Number of subjects: 5104
Study 25307297 — intervention group
Group type: COMPARATOR
Intervention: Good HRQOL
Number of subjects: 5104
Study 21962327 — intervention group
Group type: EXPERIMENTAL
Intervention: Device 1 (dedicated heart rate recording)
Number of subjects: 12
Study 21962327 — intervention group
Group type: EXPERIMENTAL
Intervention: Device 2 (dedicated heart rate recording)
Number of subjects: 12
Study 21962327 — intervention group
Group type: EXPERIMENTAL
Intervention: Device 3 (not specified)
Number of subjects: 12
Study 21962327 — intervention group
Group type: EXPERIMENTAL
Intervention: Device 4 (not specified)
Number of subjects: 12
Study 19478674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (33.0 microg kg(‐1) min(‐1))
Number of subjects: 40
Study 19478674 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 40
Study 18028056 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen sensory adapted dental environment (SDE)
Number of subjects: 19
Study 18028056 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental environment
Number of subjects: 19
Study 19146603 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation containing 3.75% glycerol and 1.25% hydrolyzed jojoba esters (K-20W)
Number of subjects: 0
Study 19146603 — intervention group
Group type: COMPARATOR
Intervention: Glycerol alone in a standard base skin care lotion
Number of subjects: 0
Study 15380582 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of electron beam radiotherapy (10 Gy)
Number of subjects: 106
Study 15380582 — intervention group
Group type: COMPARATOR
Intervention: Sham radiotherapy
Number of subjects: 106
Study 11137759 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-total-tau
Number of subjects: 9
Study 11137759 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-phospho-tau
Number of subjects: 9
Study 9355077 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil therapy
Number of subjects: 0
Study 8188016 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH: LH ratio of 3:1
Number of subjects: 0
Study 8188016 — intervention group
Group type: COMPARATOR
Intervention: FSH: LH ratio of 1:1
Number of subjects: 0
Study 8188016 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH dominant gonadotrophins
Number of subjects: 0
Study 3024959 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) administered at a daily dose of 0.5-1 mg intravenously or intramuscularly for 1-4 weeks.
Number of subjects: 64
Study 3024959 — intervention group
Group type: COMPARATOR
Intervention: ACTH therapy
Number of subjects: 64
Study 31539295 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus fluorouracil (FU), leucovorin (LV), and oxaliplatin (FOLFOX-4) induction followed by maintenance with panitumumab
Number of subjects: 199
Study 31539295 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus FU and LV
Number of subjects: 199
Study 31539295 — intervention group
Group type: COMPARATOR
Intervention: Single-agent panitumumab
Number of subjects: 199
Study 28384261 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine via caregiver Directly Observed Therapy (cDOT)
Number of subjects: 0
Study 28384261 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate (MA)
Number of subjects: 0
Study 27070526 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive behavioral therapy (12 sessions)
Number of subjects: 169
Study 25029875 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sessions of cardiac coherence biofeedback training
Number of subjects: 31
Study 25029875 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation programme only
Number of subjects: 31
Study 21505845 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic hyperventilation induced by 5 min of hypercapnic‐hyperoxic rebreathing (CO(2)‐R)
Number of subjects: 8
Study 21505845 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation (VH) of 3 min imposed by a metronome set at 25 cycles per min
Number of subjects: 8
Study 19401621 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 19401621 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 19401621 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measurement
Number of subjects: 0
Study 18217461 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine before operation
Number of subjects: 77
Study 18217461 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine at the end of operation
Number of subjects: 77
Study 18217461 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77